Overview

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Status:
RECRUITING

Trial end date:
2030-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.

Phase:

PHASE2

Details

Lead Sponsor:

BeiGene

Treatments:

zanubrutinib